2025
43-OR: Muscle mTOR Activation Attenuates Cardiomyopathy and Extends Lifespan in Muscle-Specific IRS1/IRS2 Knockout Mice
STOEHR O, TAO R, COPPS K, WHITE M. 43-OR: Muscle mTOR Activation Attenuates Cardiomyopathy and Extends Lifespan in Muscle-Specific IRS1/IRS2 Knockout Mice. Diabetes 2025, 74 DOI: 10.2337/db25-43-or.Peer-Reviewed Original ResearchMTKO miceAttenuate cardiomyopathySevere cardiomyopathyCardiac functionActivation of mTORC1Cardiac fatty acid uptakeGenetic activation of mTORC1Reducing Akt-mTOR signalingCardiac muscleDays of ageStructural cardiac parametersProgression of cardiomyopathyAkt-mTOR signalingDeletion of FoxO1Cardiac glucose uptakeEjection fractionCardiac dysfunctionTsc1 deletionKnockout miceMdKO miceCardiomyopathyCre expressionCardiac parametersFatal cardiomyopathyFatty acid uptake
2016
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016, 133: 2404-2412. PMID: 27143678, DOI: 10.1161/circulationaha.116.021612.Peer-Reviewed Original ResearchConceptsCardiac ATTR amyloidosisBone scintigraphyCardiac transthyretin amyloidosisATTR amyloidosisMyocardial radiotracer uptakeRadiotracer uptakeTransthyretin amyloidosisMajority of patientsCardiac AL amyloidosisNoninvasive diagnostic criteriaMyocardial amyloid depositsPositive predictive valueHistological confirmationMulticenter studySpecialist centresMonoclonal gammopathyCardiac amyloidosisPromising therapyAL amyloidosisATTR amyloidDiagnostic criteriaAmyloid depositsFatal cardiomyopathyPatientsScintigraphy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply